Last Updated: July 26, 2026

Details for Patent: 5,629,305

Name: Drug Patent Intelligence for US Patent 5629305
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,629,305

Title:	Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
Abstract:	A synergistic pharmaceutical combination and composition are disclosed for the treatment of gastritis and peptic ulcer containing a therapeutic amount of a proton pump inhibitor such as e.g., omeprazole or lansoprazole, which increases intragastric pH, and a therapeutic amount of an acid degradable antibacterial compound such as a penicillin or a macrolide. In particular, the combination is directed to the treatment of infections caused by Helicobacter pylori by raising the bioavailability of acid degradable antibacterial compounds.
Inventor(s):	Arne T. Eek, Sven Erik Sj ostrand
Assignee:	AstraZeneca AB
Application Number:	US08/441,766
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 5,629,305

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 5,629,305

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Sweden	9201297	Apr 24, 1992
Sweden	9300029	Jan 08, 1993

International Family Members for US Patent 5,629,305

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	466	⤷ Start Trial
African Regional IP Organization (ARIPO)	9300518	⤷ Start Trial
Austria	194286	⤷ Start Trial
Australia	4273793	⤷ Start Trial
Australia	669903	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.